Table of contents
- Trial overview
- Study design and treatment groups
- Who can participate
- What the study measures
- Why this trial matters
Trial overview
The main study in the source data is NCT06532006, a randomized, double-blinded, multicenter, Phase 3 clinical study.[1] It is testing HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 in people with locally advanced or metastatic gastroesophageal junction and gastric cancer.[1]
This trial is authorised and plans to enroll 550 participants.[1] The study is designed for first-line treatment, which means the first treatment given for this cancer.[1]
Study design and treatment groups
This is an interventional study, meaning researchers assign the treatment rather than just observing what happens.[1] The trial compares HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 plus trastuzumab and chemotherapy with trastuzumab and chemotherapy with or without pembrolizumab.[1]
The chemotherapy backbone is XELOX, which is listed in the study title.[1] The source also lists placebo versions for pembrolizumab and for HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2, showing that the study uses a blinded comparison.[1]
- Randomized means people are assigned to groups by chance, which helps make the comparison fair.[1]
- Double-blinded means the study is designed so that treatment assignment is hidden to reduce bias.[1]
- Multicenter means the trial is run at more than one study site.[1]
Who can participate
The trial is for patients with locally advanced or metastatic gastroesophageal junction and gastric cancer.[1] These terms mean the cancer is either advanced near the original site or has spread to other parts of the body.[1]
The study focuses on first-line treatment, so it is aimed at people starting treatment for this cancer rather than those who have already received several other treatments.[1]
What the study measures
The primary outcomes are progression-free survival and overall survival.[1] Progression-free survival means the time during and after treatment when the cancer does not get worse, while overall survival means how long patients live.[1]
Progression-free survival is assessed by the Blinded Independent Central Review, using RECIST v1.1.[1] RECIST v1.1 is a standard way to measure changes in tumors, such as whether they shrink, stay the same, or grow.[1]
Why this trial matters
This study is important because it tests whether adding HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 to current treatment can improve outcomes for people with advanced stomach-related cancers.[1] The Phase 3 design and larger enrollment suggest the researchers are looking for a clear answer about benefit in a real patient group.[1]
The trial also compares treatment strategies that include or exclude pembrolizumab, which helps show whether the new study drug adds value on top of existing options.[1] Because the study is first-line and includes a blinded comparison, it is built to give a strong test of the treatment approach.[1]
